Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Radiation Oncology
•
Genitourinary Cancers
How do you manage a prostate cancer patient with pelvic lymphadenopathy and a single enlarged PSMA PET+ gastrohepatic node?
Do you consider radiation therapy in such a case?
Related Questions
What are your top takeaways from ASCO GU 2025?
What dose/fractionation would you recommend for a prostate patient who previously received 1 of 5 planned fractions SBRT in 2020?
What is your radiation approach/details for regionally involved prostate cancer (N1)?
What adjuvant treatment would you offer a patient who underwent cystoprostatectomy for a muscle invasive bladder cancer and discovered to also have prostate cancer?
How would you manage a patient who developed an intraprostatic abscess after SpaceOAR injection, prior to starting radiation?
What is your preferred approach in a patient unable to fill their bladder during prostate radiotherapy?
How do you manage bladder spasms during pelvic radiotherapy?
Do you recommend neoadjuvant 177Lu-PNT2002 followed by MDT per the LUNAR trial as your preferred treatment approach for oligorecurrent prostate cancer, as opposed to MDT and PSMA-radioligand therapy used as temporally separate treatments?
How do you counsel/advise patients when asked to compare ultrahypofractionated radiotherapy with the TULSA procedure?
Which patients, if any, do you offer transdermal estradiol as a method of ADT instead of LHRH agonists?